Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.98 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.98 |
| ▸ | MYLK | Q15746 | 1/20 | 0.98 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23818372 | 1.00 | MELK (1.00) | MELKFLT3CAMK2GCAMK2DMYLK | |
| Hydrochloric Acid SCHEMBL30341843 | 0.99 | MELK (1.00) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20290866 | 0.87 | MELK (0.77) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291161 | 0.85 | MELK (0.74) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20290500 | 0.85 | MELK (0.73) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291125 | 0.85 | MELK (0.73) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291298 | 0.83 | MELK (0.71) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20290838 | 0.82 | MELK (0.70) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291160 | 0.82 | MELK (0.69) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20290843 | 0.81 | MELK (0.67) | MELKFLT3CAMK2GCAMK2DMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12098183-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-09-24 | — | — | US | disclosed |
| US-12065477-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240076349-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-07 | — | — | US | disclosed |
| US-11919940-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-03-05 | — | — | US | disclosed |
| US-20240034769-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| US-11858978-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11840562-B2 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-12-12 | — | — | US | disclosed |
| US-20230365651-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20230312680-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20230002473-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20230002474-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-20220356227-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| EP-4035675-A2 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Immatics Biotechnologies GmbH (DE) | 2022-08-03 | — | — | EP | disclosed |
| US-11345737-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| US-11248035-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | MELK 852/4885FLT3 3835/4885CAMK2G 292/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | MELK 750/4885FLT3 3226/4885CAMK2G 1316/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | MELK 852/4885FLT3 3835/4885CAMK2G 292/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | MELK 852/4885FLT3 3835/4885CAMK2G 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.